Cancer medicine · 2026
Apparent Survival Benefit of Postoperative Radioactive Iodine in Lymph Node-Positive Papillary Thyroid Carcinoma: A Negative-Control Analysis for Unmeasured Confounding.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Tengfei, Qiao Junli, Mao Mengxuan, Guo Qiang, Yang Fei
Аннотация
BACKGROUND: Observational studies report an overall-survival advantage for postoperative radioactive iodine (RAI) in lymph node-positive papillary thyroid carcinoma (PTC), but such estimates are vulnerable to confounding by indication and to bias from immortal time and the healthy-user effect. We assessed the credibility of this apparent benefit rather than RAI efficacy itself.
METHODS: Using SEER (2010-2015), we assembled a cohort of N1b, M0, totally thyroidectomized PTC patients and applied a 3-month landmark analysis (sensitivity analyses at 1 and 6 months) with stabilized inverse-probability-of-treatment weighting. We estimated RAI effects on overall survival, cancer-specific survival, and relative survival, and on a negative-control outcome-non-thyroid-cancer death-that RAI cannot plausibly affect. Residual confounding was quantified with E-values.
RESULTS: Among 4275 patients, RAI showed an apparent survival benefit in direction across all three endpoints. However, the negative-control outcome likewise showed an apparent benefit (IPTW hazard ratio 0.713, 95% CI 0.562-0.906), indicating residual confounding not removed by weighting. The apparent survival benefits therefore could not be distinguished from unmeasured confounding.
CONCLUSIONS: In registry data lacking key confounders, a negative control identifies the apparent RAI survival benefit as a candidate artifact of unmeasured confounding. The findings neither support nor refute RAI efficacy.
METHODS: Using SEER (2010-2015), we assembled a cohort of N1b, M0, totally thyroidectomized PTC patients and applied a 3-month landmark analysis (sensitivity analyses at 1 and 6 months) with stabilized inverse-probability-of-treatment weighting. We estimated RAI effects on overall survival, cancer-specific survival, and relative survival, and on a negative-control outcome-non-thyroid-cancer death-that RAI cannot plausibly affect. Residual confounding was quantified with E-values.
RESULTS: Among 4275 patients, RAI showed an apparent survival benefit in direction across all three endpoints. However, the negative-control outcome likewise showed an apparent benefit (IPTW hazard ratio 0.713, 95% CI 0.562-0.906), indicating residual confounding not removed by weighting. The apparent survival benefits therefore could not be distinguished from unmeasured confounding.
CONCLUSIONS: In registry data lacking key confounders, a negative control identifies the apparent RAI survival benefit as a candidate artifact of unmeasured confounding. The findings neither support nor refute RAI efficacy.